Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
Net Sales
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Operating Profit (PBDIT) excl Other Income
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Interest
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit After Tax
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024
Compare Profit and Loss Results of Astrazeneca Phar
Figures in Cr
standalone - Profit And Loss Results
Change(INR)
Change(%)
No of Months
12
12
Operating Income
1,716.00
989.00
727.00
73.51%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
1,716.00
989.00
727.00
73.51%
Expenditure (Ex Depriciation)
Stock Adjustments
-332.00
-18.00
-314.00
-1,744.44%
Raw Materials Consumed
1,295.00
566.00
729.00
128.80%
Power & Fuel Cost
5.00
29.00
-24.00
-82.76%
Employee Cost
257.00
80.00
177.00
221.25%
Operating Expenses
18.00
41.00
-23.00
-56.10%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
93.00
28.00
65.00
232.14%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
13.00
8.00
5.00
62.50%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
1,462.00
764.00
698.00
91.36%
Operating Profit (PBDIT) excl Other Income
253.00
225.00
28.00
12.44%
Other Income
40.00
18.00
22.00
122.22%
Operating Profit (PBDIT)
294.00
243.00
51.00
20.99%
Interest
1.00
5.00
-4.00
-80.00%
Profit before Depriciation and Tax
293.00
237.00
56.00
23.63%
Depreciation
39.00
24.00
15.00
62.50%
Profit Before Taxation & Exceptional Items
253.00
213.00
40.00
18.78%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
156.00
213.00
-57.00
-26.76%
Provision for Tax
40.00
54.00
-14.00
-25.93%
Profit After Tax
115.00
159.00
-44.00
-27.67%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
578.00
308.00
270.00
87.66%
Profit Available for appropriations
693.00
467.00
226.00
48.39%
Appropriations
693.00
467.00
226.00
48.39%
Equity Dividend (%)
1600%
30%
1,570.00
Earnings Per Share
46.3
19.91
26.39
132.55%
Profit And Loss - Net Sales
Net Sales 1,716.29 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 32.48% vs 29.17% in Mar 2024
Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 253.97 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 37.69% vs 11.71% in Mar 2024
Profit And Loss - Interest
Interest 1.46 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is 21.67% vs 90.48% in Mar 2024
Profit And Loss - Profit After Tax
Profit After Tax 115.74 Cr
in Mar 2025Figures in Cr
YoY Growth in year ended Mar 2025 is -28.34% vs 62.66% in Mar 2024






